| Last Action | 01/21/20: posted in committee |
|---|---|
| Title | AN ACT relating to prescription drugs. |
| Bill Documents | Introduced |
| Fiscal Impact Statement | Health Mandate |
| Bill Request Number | 25 |
| Sponsors | D. Bentley, T. Bojanowski, R. Bridges, D. Frazier, K. King, C. Massey, P. Minter, P. Pratt, M. Sorolis, C. Stevenson, R. Webber, S. Westrom |
| Summary of Original Version | Create various new sections of KRS Chapter 315 to define terms; to require the Cabinet for Health and Family Services to annually compile lists of certain prescription drugs deemed to be essential to treating diabetes; to require drug manufacturers to annually report to the cabinet certain information related to the cost of manufacturing and marketing such drugs and factors that contributed to any price increase; require pharmacy benefit managers to annually report to the cabinet certain information related to prescription drug rebates for such drugs; to require the cabinet to annually submit to the Legislative Research Commission a report that summarizes the information provided to the cabinet by manufacturers and pharmacy benefit managers; to exempt information and data reported by manufacturers and pharmacy benefit managers to the cabinet from disclosure pursuant to KRS 61.870 to 61.884; to require the cabinet to promulgate administrative regulations; amend KRS 315.990 to establish a penalty for failure to report; amend KRS 304.17A-164 to restrict cost-sharing amounts charged by insurers and pharmacy benefit managers; to prohibit insurers and pharmacy benefit managers from restricting a pharmacist's ability to inform patients about and to sell less expensive alternative drugs; amend KRS 304.17A-505 and 304.17C-030 to require disclosure of information related to drug formularies; to create various new sections of KRS Chapter 367 to define terms; to prohibit manufacturers and wholesalers of off-patent or generic prescription drugs from engaging in unrestricted price increases; to require the secretary of the Cabinet for Health and Family Services to report certain price increases to the Attorney General; to establish that certain price increases for off-patent or generic drugs constitute a violation of KRS 367.170; to establish penalties; and certain sections EFFECTIVE January 1, 2021. |
| Index Headings of Original Version |
Diseases - Diabetes, insulin price reporting requirements, establishment of Drugs and Medicines - Insulin, price reporting requirements, establishment of Drugs and Medicines - Prescription drugs, unrestricted price increases, prohibition of Insurance, Health - Cost-sharing amounts, restrictions on Insurance, Health - Drug formulary changes, require disclosure of Pharmacists - Sale of less expensive alternative drugs, permitted Administrative Regulations and Proceedings - Cabinet for Health and Family Services, prescription drug price reporting Attorney General - Prescription drugs, unrestricted price increases, prohibition of Reports Mandated - Cabinet for Health and Family Services, insulin drug prices Effective Dates, Delayed - Cost-sharing amounts, restrictions on Effective Dates, Delayed - Drug formulary changes, require disclosure of Health Benefit Mandate - Prescription drug price reporting |
| 01/13/20 |
|
|---|---|
| 01/15/20 |
|
| 01/21/20 |
|
Last updated: 10/27/2020 12:10 PM (EDT)
To receive notice when the record is updated follow @LRCTweetBot. @LRCTweetBot